Aichi Cancer Center /ID# 282273

Nagoya, Aichi-ken 464-8681

1 studies enrolling now · 1 studies all time

What they study most

Head and Neck Squamous Cell Carcinoma

Studies at this site

• A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Starting soon